Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients
An Extension to a 12-month, Open-label, Randomised, Multicenter, Sequential Cohort, Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of Oral AEB071 Versus Cyclosporine in Combination With Everolimus, Basiliximab and Corticosteroids in de Novo Adult Renal Transplant Recipients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Cordoba, Argentina, X5022CPU
- Novartis Investigative Site
-
-
Buenos Aires
-
San Martin, Buenos Aires, Argentina, C1107BEA
- Novartis Investigative Site
-
-
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Novartis Investigative Site
-
-
South Australia
-
Woodville, South Australia, Australia, 5011
- Novartis Investigative Site
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Novartis Investigative Site
-
-
-
-
-
Innsbruck, Austria, A-6020
- Novartis Investigative Site
-
-
-
-
-
Gent, Belgium, 9000
- Novartis Investigative Site
-
-
-
-
RS
-
Porto Alegre, RS, Brazil, 90020-090
- Novartis Investigative Site
-
-
SP
-
São Paulo, SP, Brazil, 04023-900
- Novartis Investigative Site
-
-
-
-
-
Bogotá, Colombia
- Novartis Investigative Site
-
Cali, Colombia
- Novartis Investigative Site
-
-
-
-
-
Praha 4, Czech Republic, 140 00
- Novartis Investigative Site
-
-
-
-
-
Brest, France, 29200
- Novartis Investigative Site
-
Nantes Cedex, France, 44035
- Novartis Investigative Site
-
Toulouse Cedex 4, France, 31054
- Novartis Investigative Site
-
-
-
-
-
Berlin, Germany, 10117
- Novartis Investigative Site
-
Heidelberg, Germany, 69120
- Novartis Investigative Site
-
-
-
-
MI
-
Milano, MI, Italy, 20162
- Novartis Investigative Site
-
Milano, MI, Italy, 20122
- Novartis Investigative Site
-
-
-
-
-
Rotterdam, Netherlands, 3015 CE
- Novartis Investigative Site
-
-
-
-
-
Oslo, Norway, 0424
- Novartis Investigative Site
-
-
-
-
-
Singapore, Singapore, 119074
- Novartis Investigative Site
-
-
-
-
-
Banska Bystrica, Slovakia, 975 17
- Novartis Investigative Site
-
-
Slovak Republic
-
Kosice, Slovak Republic, Slovakia, 041 90
- Novartis Investigative Site
-
-
-
-
-
Madrid, Spain, 28034
- Novartis Investigative Site
-
-
Barcelona
-
Hospitalet de Llobregat, Barcelona, Spain, 08907
- Novartis Investigative Site
-
-
-
-
-
Zurich, Switzerland, 8091
- Novartis Investigative Site
-
-
-
-
-
Taipei, Taiwan, 10002
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Patient has been maintained on study drug for 12 months in the core study
Exclusion criteria:
- Not applicable
- Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: cyclosporine (reduced exposure) / everolimus
|
twice daily
|
|
Experimental: AEB071 300 mg b.i.d. / everolimus
|
twice daily
|
|
Experimental: AEB071 200 mg b.i.d. / everolimus
|
twice daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
renal function as measured by the glomerular filtration rate (GFR) using the modification of diet in renal disease (MDRD) formula
Time Frame: at months 15, 18, 21, 24, 30, 36, 42, 48, 54 and 60 months after transplantation
|
at months 15, 18, 21, 24, 30, 36, 42, 48, 54 and 60 months after transplantation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
efficacy failure, defined as a composite efficacy endpoint of treated biopsy proven acute rejection, graft loss, death or loss to follow-up
Time Frame: at months 15, 18, 21, 24, 30, 36, 42, 48, 54 and 60 months after transplantation
|
at months 15, 18, 21, 24, 30, 36, 42, 48, 54 and 60 months after transplantation
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Antifungal Agents
- Calcineurin Inhibitors
- Everolimus
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
Other Study ID Numbers
- CAEB071A2206E1
- 2008-000531-18 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.